MoonLake Investors Courted by Law Firms as Lead‑Plaintiff Deadline Nears in SDNY Securities Case
The suit stems from September trial data that preceded a near‑90% one‑day drop in MoonLake’s share price.
Overview
- A securities class action is pending in the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, No. 1:25-cv-08612.
- Multiple plaintiff firms are urging shareholders to move for lead‑plaintiff status by December 15, 2025, covering a putative class period from March 10, 2024 through September 29, 2025.
- Complaints allege MoonLake made false or misleading statements about sonelokimab’s Nanobody advantages and failed to disclose that SLK and BIMZELX target IL‑17A and IL‑17F.
- MoonLake’s September 28, 2025 Week 16 VELA disclosure included VELA‑2 missing its primary endpoint, after which the stock fell about $55.74 to close at $6.24 on September 29.
- The cases remain at an early stage with no class certified as firms including Glancy Prongay, Gross, Faruqi & Faruqi, Rosen, Schall, DJS, Levi & Korsinsky, Hagens Berman, and Frank R. Cruz solicit investors and information.